Clinical Trial

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-28; most recent amendment 2025-12-08.
Status change: Not Yet Recruiting → Recruiting 2024-11-27
Trial Details
NCT Number NCT06489249
Lead Sponsor University of Iowa
Conditions Electronic Cigarette Use, Endothelial Dysfunction, Inflammation
Enrollment 24 participants
Start Date 2024-08-15
Primary Completion 2026-06 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-15